Monitor for updates on PDS0301 Phase 3 trial initiation and PDS0101 partnership progress. The new directors' backgrounds in corporate development and commercialization may signal a shift toward partnership or out-licensing strategy.
Price Chart
Executive Summary
PDS Biotechnology announced the resignation of four directors (Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and Otis Brawley) and the appointment of three new independent directors (Deborah Ramsdell, John Dawson, and Bruce Wendel) with experience in drug development, commercialization, and corporate development. The board was reconstituted to seven members with new committee assignments. The resignations were not due to any disagreement with the company.
Key Facts
- Four directors resigned effective October 18, 2026, none due to any disagreement with the company.
- Three new directors appointed: Deborah Ramsdell, John Dawson CBE, and Bruce Wendel.
- Board size fixed at seven directors.
- New directors received nonqualified stock options to purchase 22,700 shares each, vesting over three years.
- Committees reconstituted: Audit (Banaag chair, Dawson, Wendel), Compensation (Soon-Shiong chair, Banaag, Dawson), Nominating/Governance (Wendel chair, Iliev, Ramsdell).
- Company advancing PDS0301 toward Phase 3 trial in metastatic colorectal cancer and pursuing partnership strategy for PDS0101.
Financial Impact
Each new director received a nonqualified stock option for 22,700 shares; no other financial terms disclosed.
Risk Factors
- No financial data or guidance provided in the filing.
- Board turnover could signal strategic shift but no disagreement stated.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-040181 |
| Document: ef20084000_ex99-1.htm | 0001140361-26-040181 |
| Document: 0001140361-26-040181-index-headers.html | 0001140361-26-040181 |
| Document: 0001140361-26-040181-index.html | 0001140361-26-040181 |
| Document: 0001140361-26-040181.txt | 0001140361-26-040181 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 3 | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.31 (+5.66%) |
Oct 20, 2026 6d ago | 8-K | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.31 (+5.66%) |
Oct 20, 2026 7d ago | 8-K | $0.9605 $1.24 | ▲ +29.10% | ▲ +28.57% | $1.31 (+36.41%) |
Oct 14, 2026 12d ago | S-3 | $1.30 $1.13 | ▲ +13.08% | ▲ +11.97% | $1.31 (−0.78%) |
Oct 6, 2026 21d ago | 8-K | $1.05 $1.07 | ▲ +1.91% | ▲ +2.15% | $1.31 (+25.38%) |
Sep 22, 2026 5w ago | 8-K | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.31 (+43.98%) |
Sep 22, 2026 5w ago | Press Release | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.31 (+43.98%) |
Sep 21, 2026 5w ago | SC 13D | $0.9100 $0.8240 | ▼ −9.45% | ▼ −8.73% | $1.31 (+43.98%) |
Sep 4, 2026 7w ago | 8-K | $0.3000 $0.2930 | ▲ +2.33% | ▲ +1.87% | $1.31 (−336.73%) |
Aug 19, 2026 9w ago | 8-K | $0.2089 $0.2185 | ▲ +4.60% | ▲ +4.19% | $1.31 (+527.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers